Traws Pharma, Inc. (NASDAQ: TRAW) shared encouraging findings on its investigational antiviral drug, tivoxavir marboxil (TXM) ...

INVESTORS AND SECURITY HOLDERS ARE URGED TO READ CAREFULLY AND IN THEIR ENTIRETY THE PROXY STATEMENT (INCLUDING ANY AMENDMENTS OR SUPPLEMENTS THERETO) FILED BY ATEA AND ANY OTHER RELEVANT DOCUMENTS TO ...

The COVID-19 pandemic highlighted the urgent need for effective therapeutic agents against SARS-CoV-2. Although vaccines ...

This site uses cookies to enhance your user experience. By continuing to use this site you are agreeing to our COOKIE POLICY.

Poster underscores Tivoxavir Marboxil’s potential for the treatment of bird flu, supported by 100% survival in a rodent challenge model, potent ...

Gene therapy, with its offer of a possible cure for rare diseases like sickle cell, is losing early investors to ...

Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for ...

Back in 2021, at the height of the pandemic, scientists at Pfizer revealed the development of a novel antiviral molecule, ...

Scientists have found that an oral antiviral drug successfully prevents monkeys from dying after an Ebola infection, an advance that may prevent future outbreaks of the deadly virus. The Ebola virus ...

New research this month shows that the experimental antiviral obeldesivir prevented up to 100% of deaths in monkeys infected ...

As the H5N1 avian influenza outbreak continues, scientists are working to better understand the virus's threat to human ...